- Home
- ATYR
as 04-02-2025 4:00pm EST
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 327.0M | IPO Year: | 2015 |
| Target Price: | $18.60 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.42 - $4.66 | Next Earning Date: | 03-13-2025 |
| Revenue: | $235,000 | Revenue Growth: | -33.43% |
| Revenue Growth (this year): | 1387.23% | Revenue Growth (next year): | 873.22% |
Latest aTyr Pharma Inc. Common Stock News
ATYR Breaking Stock News: Dive into ATYR Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
8 days ago
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
GuruFocus.com
20 days ago
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...
GlobeNewswire
21 days ago
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
GlobeNewswire
22 days ago
aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
GlobeNewswire
a month ago
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
GlobeNewswire
a month ago
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
GlobeNewswire
a month ago
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
Compare ATYR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATYR aTyr Pharma Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.